India’s Panacea Biotec partners with US firm to make Covid-19 vaccine
Team Udayavani, Jun 12, 2020, 12:05 PM IST
Indian biotech firm Panacea Biotec Ltd will partner with U.S.based Refana Inc to make a potential vaccine for Covid-19
Under the partnership, Panacea Biotec will be responsible for product development and commercial manufacturing of an inactivated virus-based vaccine
The collaboration aims to make more than 500 million doses of the vaccine candidate, with over 40 million doses expected to be available early next year.
The company said that after the CGMP process, the first phase of the human trial will be held by October and they will be able to conduct the third phase of the trial on a large scale.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Plastic waste could double by 2050, researchers find, suggest policies to address issue
Six scholars, including two women, win Infosys Prize 2024
6G technology and intelligent receivers will ease way for army intelligence operations: IIT official
India successfully test-fires long-range cruise missile
IISc scientists develop enzyme-based solution to break antibiotic-resistant biofilms
MUST WATCH
Latest Additions
Violence continues in Manipur; BJP and Congress offices vandalised
Delhi Air Pollution | No physical classes for students, barring class 10 and 12: CM Atishi
Maharashtra Assembly Polls 2024 | Congress has always insulted Dr Ambedkar: Chirag Paswan
PM Modi arrives in Brazil to attend G20 Summit on tour’s second leg
Mangaluru: Drive to remove unauthorized flexes and banners begins
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.